Icon

TREANDA (nda022249)- (25MG/VIAL,100MG/VIAL)

BENDAMUSTINE HYDROCHLORIDE CEPHALON
25MG/VIAL,100MG/VIAL
Yes Yes
2031-Apr-26 2013-Mar-20
2015-Mar-20 None
None No
TREANDA is an alkylating drug indicated for treatment of patients with:  Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.  Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
9 6 5
Total Other Developers 1
Drugs with Suitability No
25MG/VIAL ** ** - - -
100MG/VIAL ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 4
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ****** ******** ***** *************** ******* *********** **** **. ***/***-****** / **** **.***/****-*********** , *******-***** ******* , ****** -******, ******, *********, ******* ******, ***** (***) ***
****** ***** ****** ***** ****** ************ ******* *********** ****-*, **. **. ***, *** & ***, ******* *******, ********* ******, *******-**********, ********* ******, ***** (***) ***
****** ****** ***** ****** ******* *********** **** * & **** **, ***** *, ***** *, ************* ******* ******** **** (**** ), *******, *************, ****** ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.